CCEL Cryo-Cell International, Inc.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. It is also involved in the manufacturing of PrepaCyte CB processing system units for processing umbilical cord blood stem cells. In addition, the company provides cold storage services to third-party pharmaceutical companies and medical institutions. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.…
Industry Peers
Medical Care FacilitiesKey Statistics
About Cryo-Cell International (NYSEAMERICAN: CCEL)
›
Cryo-Cell International (NYSEAMERICAN: CCEL) is listed on NYSE American, where its shares trade in USD. It belongs to the Medical Care Facilities industry, part of the Healthcare sector, and reports about 72 employees.
The shares were at 4.850 USD on 13 November 2026, up 19.8% over 52 weeks. Its 52-week range is 2.720 USD to 5.443 USD: the price is 10.9% below the high and 78.3% above the low.
Its market capitalisation is 39.10M USD.
Cryo-Cell International reports return on equity of 13.1%, an operating margin of 0.6% and flat revenue year over year.
Its debt exceeds its cash by 4.59M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health.